Acceleron Pharma Science & Pipeline

Science & Pipeline

Hematology

Hematology

REBLOZYL®
(luspatercept-aamt)

Phase 1Ph1Phase 2Ph2Phase 3Ph3ApprovedApp
REBLOZYL® (luspatercept-aamt)
Beta-Thalassemia**
Beta-Thalassemia**
Myelodysplastic Syndromes**
Myelodysplastic
Syndromes**
luspatercept-aamt
luspatercept-aamt
Beta-Thalassemia

non-transfusion dependent

Beta-Thalassemia

non-transfusion dependent

BEYOND Trial*BEYOND Trial*BEYOND Trial*
Myelodysplastic Syndromes
Myelodysplastic
Syndromes
COMMANDS Trial*COMMANDS Trial*COMMANDS Trial*
Myelofibrosis
Myelofibrosis
INDEPENDENCE Trial (planned)*INDEPENDENCE Trial (planned)*INDEP Trial (planned)*

* Bristol Myers Squibb-sponsored

** Reblozyl is approved in the United States for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions, and for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). It is not approved for any other use in the United States, or for any use in any other country.

Pulmonary

Sotatercept
Phase 1Ph1Phase 2Ph2Phase 3Ph3ApprovedApp

Pulmonary

Sotatercept
 
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
PULSAR TrialPULSAR TrialPULSAR Trial
SPECTRA Exploratory TrialSPECTRA Exploratory TrlSPECTRA Trial
ACE-1334
Pulmonary Disease
Pulmonary Disease